- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Eli Lilly's Inluriyo approved by FDA for breast cancer | ||
| Fr | FDA accepts supplemental New Drug Application for Pharming's paediatric immunodeficiency therapy | ||
| Fr | Porterhouse appoints Jennifer Stewart as Medical Director in US | ||
| Fr | What does it mean to improve outcomes for patients with chronic conditions? | ||
| Do | BMS, Takeda and Astex join AI training consortium | ||
| Do | J&J's Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis | ||
| Do | Smarter strategies for systematic literature reviews | ||
| Mi | Pfizer agrees pricing and distribution deal with US government | ||
| Mi | Amgen commits $650m to US manufacturing expansion | ||
| Mi | EU medicine shortages hit record highs in 2023 and 2024 | ||
| Mi | From instinct to insights: how data is transforming medical communications | ||
| Di | Lilly's early Alzheimer's disease treatment approved in the EU | ||
| Di | GSK names Luke Miels as next CEO | ||
| Di | Launch excellence: innovative thinking meets insightful strategy | ||
| Mo | Roche's Lunsumio receives positive CHMP opinion for follicular lymphoma | ||
| Mo | University of Liverpool identifies new class of antibiotic in fight against AMR | ||
| Mo | Biopharma 2030 challenge: scaling product launches without growing teams | ||
| 26.09. | Ipsen's tumour treatment receives MHRA marketing authorisation | ||
| 26.09. | NHS launches National Commission to strengthen AI regulation | ||
| 26.09. | Will data and AI prove to be the game-changer that transforms launch excellence? | ||
| 26.09. | New survey: Europeans seek better health equity in breast cancer awareness | ||
| 25.09. | Novartis announces new data supporting MS therapy Kesimpta | ||
| 25.09. | EMA reaffirms guidance on paracetamol use during pregnancy | ||
| 24.09. | Lilly to spend $6.5bn on second of four US manufacturing facilities | ||
| 24.09. | SAY Communications teams up with Overcoming MS, a multiple sclerosis charity |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .